5 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2028. from the record
Of the 8 now held by other companies, 8 name JCR Pharmaceuticals Co. Ltd. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Jul 2028
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2035 · High confidence
Also notable
Ends Jul 2028 · High confidence
Also notable
Ends Oct 2030 · High confidence
Compositions and Methods Related to Structures That Cross the Blood Brain Barrier
US 10,906,981
Cited by 17 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2035.
Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS
US 8,974,791
The most cited patent in this portfolio, cited by 26 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2028.
Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS
US 11,028,156
A family of 6 related applications built on the 2021 grant. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Aug 2027 · High confidence
The most cited patent in this portfolio, cited by 69 later US patents, top 10% of utility patents granted in 2010 in our data. Protection runs to 2027.
now held by JCR Pharmaceuticals Co., Ltd.
Also notable
Ends Jun 2031 · High confidence
Cited by 48 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by JCR Pharmaceuticals Co., Ltd.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- Sep 29Assignment recorded on 1 record: Armagen Technologies, Inc. to Armagen, Inc. Recorded Sep 29, 2026, executed Jul 11, 2014. Conveyance as recorded: Change of Name. A recorded assignment is a filed document, not a statement of current ownership. Reel 76607, frame 692.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS | 2 in force | to Jun 2031 |
| Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS | 2 in force | to Jul 2028 |
| Compositions and Methods Related to Structures That Cross the Blood Brain Barrier | 1 in force | to Jul 2035 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,974,791 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS In force · High confidence | In force | High confidence | |
| US 11,512,145 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS In force · High confidence | In force | High confidence | |
| US 11,028,156 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS In force · High confidence | In force | High confidence | |
| US 12,043,661 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS In force · High confidence | In force | High confidence | |
| US 10,906,981 | Compositions and Methods Related to Structures That Cross the Blood Brain Barrier held by Armagen Technologies, Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 8 patents in force now held by others · 11 patents ended · 6 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.